BACKGROUND:Interferon-β1a (IFNB) and glatiramer acetate (GA) are distinct therapies which are both partially effective for relapsing MS. It is not known if combining the two treatments would be more effective. OBJECTIVE: To review the rationale, design, and baseline characteristics of the CombiRx study of combined treatment with IFNB and GA. METHODS: The key inclusion criteria included a diagnosis of relapsing MS, at least 2 episodes of MS activity in the previous 3 years, expanded disability status scale of 0 to 5.5, and no prior treatment with either IFNB or GA. Subjects were randomized to IFNB+GA, IFNB monotherapy, or GA monotherapy in a 2:1:1 ratio. RESULTS:From 2005 to 2009, we enrolled 1008 subjects. The participants were 72.4% female and 87.6% Caucasian with a mean age of 37.7 years. The median duration of symptoms was 2 years at entry into the study, and the mean EDSS was 2.1. On the baseline MRI, the mean total lesion load was 12.2 ml, and 40% of the participants had enhancing lesions. CONCLUSION: We have recruited a population of patients with clinical and MRI characteristics typical for early MS. The study results will aid in deciding on the optimum early treatment. This trial should serve as a model for future studies of combination therapy.
RCT Entities:
BACKGROUND: Interferon-β1a (IFNB) and glatiramer acetate (GA) are distinct therapies which are both partially effective for relapsing MS. It is not known if combining the two treatments would be more effective. OBJECTIVE: To review the rationale, design, and baseline characteristics of the CombiRx study of combined treatment with IFNB and GA. METHODS: The key inclusion criteria included a diagnosis of relapsing MS, at least 2 episodes of MS activity in the previous 3 years, expanded disability status scale of 0 to 5.5, and no prior treatment with either IFNB or GA. Subjects were randomized to IFNB+GA, IFNB monotherapy, or GA monotherapy in a 2:1:1 ratio. RESULTS: From 2005 to 2009, we enrolled 1008 subjects. The participants were 72.4% female and 87.6% Caucasian with a mean age of 37.7 years. The median duration of symptoms was 2 years at entry into the study, and the mean EDSS was 2.1. On the baseline MRI, the mean total lesion load was 12.2 ml, and 40% of the participants had enhancing lesions. CONCLUSION: We have recruited a population of patients with clinical and MRI characteristics typical for early MS. The study results will aid in deciding on the optimum early treatment. This trial should serve as a model for future studies of combination therapy.
Authors: J S Wolinsky; P A Narayana; J H Noseworthy; F D Lublin; J N Whitaker; A Linde; P Gjörstrup; H C Sullivan Journal: Neurology Date: 2000-05-09 Impact factor: 9.910
Authors: J A Cohen; G R Cutter; J S Fischer; A D Goodman; F R Heidenreich; A J Jak; J E Kniker; M F Kooijmans; J M Lull; A W Sandrock; J H Simon; N A Simonian; J N Whitaker Journal: Arch Neurol Date: 2001-06
Authors: J A Cohen; P A Calabresi; S Chakraborty; K R Edwards; T Eickenhorst; W L Felton; E Fisher; R J Fox; A D Goodman; C Hara-Cleaver; G J Hutton; P B Imrey; D M Ivancic; B F Mandell; J E Perryman; T F Scott; T T Skaramagas; H Zhang Journal: Mult Scler Date: 2008-01-21 Impact factor: 6.312
Authors: L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham Journal: Ann Neurol Date: 1996-03 Impact factor: 10.422
Authors: C Ford; A D Goodman; K Johnson; N Kachuck; J W Lindsey; R Lisak; C Luzzio; L Myers; H Panitch; J Preiningerova; A Pruitt; J Rose; H Rus; J Wolinsky Journal: Mult Scler Date: 2010-01-27 Impact factor: 6.312
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: Minal J Bhanushali; Tarah Gustafson; Steve Powell; Robin A Conwit; Jerry S Wolinsky; Gary R Cutter; Fred D Lublin; Stacey S Cofield Journal: Clin Trials Date: 2014-04 Impact factor: 2.486
Authors: Kathryn C Fitzgerald; Kicheol Kim; Matthew D Smith; Sean A Aston; Nicholas Fioravante; Alissa M Rothman; Stephen Krieger; Stacey S Cofield; Dorlan J Kimbrough; Pavan Bhargava; Shiv Saidha; Katharine A Whartenby; Ari J Green; Ellen M Mowry; Gary R Cutter; Fred D Lublin; Sergio E Baranzini; Philip L De Jager; Peter A Calabresi Journal: Brain Date: 2019-09-01 Impact factor: 13.501
Authors: Refaat E Gabr; Ivan Coronado; Melvin Robinson; Sheeba J Sujit; Sushmita Datta; Xiaojun Sun; William J Allen; Fred D Lublin; Jerry S Wolinsky; Ponnada A Narayana Journal: Mult Scler Date: 2019-06-13 Impact factor: 6.312
Authors: Fred D Lublin; Stacey S Cofield; Gary R Cutter; Robin Conwit; Ponnada A Narayana; Flavia Nelson; Amber R Salter; Tarah Gustafson; Jerry S Wolinsky Journal: Ann Neurol Date: 2013-03-11 Impact factor: 10.422
Authors: Sushmita Datta; Terrell D Staewen; Stacy S Cofield; Gary R Cutter; Fred D Lublin; Jerry S Wolinsky; Ponnada A Narayana Journal: Mult Scler Relat Disord Date: 2015-01-17 Impact factor: 4.339
Authors: Ponnada A Narayana; Koushik A Govindarajan; Priya Goel; Sushmita Datta; John A Lincoln; Stacy S Cofield; Gary R Cutter; Fred D Lublin; Jerry S Wolinsky Journal: Neuroimage Clin Date: 2012-11-30 Impact factor: 4.881
Authors: Douglas L Arnold; Peter A Calabresi; Bernd C Kieseier; Sarah I Sheikh; Aaron Deykin; Ying Zhu; Shifang Liu; Xiaojun You; Bjoern Sperling; Serena Hung Journal: BMC Neurol Date: 2014-12-31 Impact factor: 2.474
Authors: Aliza Bitton Ben-Zacharia; Malvin N Janal; Abraham A Brody; Jerry Wolinsky; Fred Lublin; Gary Cutter Journal: J Cent Nerv Syst Dis Date: 2021-11-06